CEACAM5 and adenocarcinoma in situ: Importantly, the MP‐NN model demonstrated better performance for the detection of early‐stage LUAD patients (stage 0‐II) from HC/LBD patients than CEA (p < 0.001) and the Met‐NN (p < 0.001) and even for the detection of patients with adenocarcinoma in situ (stage 0) (Table 1).